A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Philips and Vithas Sign a 5 Year Strategic Agreement

January 25, 2021

Philips and Vithas Group, Spain’s second-largest private healthcare group, today signed a 5-year innovation and collaboration agreement in the areas of precision diagnosis and image-guided intervention.

The agreement will allow Vithas Group hospitals and medical centers to benefit from the latest innovations in diagnostic imaging technology, healthcare informatics, and equipment for minimally-invasive interventional procedures. Vithas Group hospitals and clinics offer healthcare and advanced medical care in thirteen provinces in seven autonomous regions of Spain.

Under the terms of the agreement, Philips will deliver a technology management model that ensures Vithas Group’s current and future health technology needs in the relevant areas are met, together with the associated maintenance, updating, and equipment and system renewal needs. This management model will enable Vithas Group to achieve better results, provide optimal care at lower cost, and deliver a better experience for its patients and healthcare professionals.

In addition, Vithas will become a ‘reference technology partner’ for Philips in Spain, which means that its hospitals and medical centers will be able to implement new advances and innovations developed by Philips, before standard commercialization of these solutions in Spain.

“This new alliance with Philips integrates cutting-edge technology, healthcare excellence, innovation, and research, which are the fundamental pillars on which we support our commitment to always seek the best experience for our patients,” said Dr. Pedro Rico, CEO of Vithas Group. “Furthermore, our professionals will have the most advanced technological solutions at all times, which will reinforce the quality of care and facilitate their research work.”

“We are very excited about the trust placed in Philips and convinced that, through this collaboration agreement, Vithas will have all the technology and innovation necessary to continue achieving the best health results and the best experience for its patients and its healthcare professionals,” said Juan Sanabria, President of Philips Ibérica. “We are proud to become the technological partner and strategic ally of a group as important as Vithas.”

The most advanced diagnostic imaging technology

The agreement includes the replacement of Vithas Group’s existing MR imaging equipment with Philips’ latest innovative MR systems, which stand out for their image quality and patient comfort, and because they do not consume helium, also stand out for their sustainability. Philips will also install hybrid operating room solutions, including its latest ceiling mounted live-image guidance system for minimally-invasive interventional therapy, allowing Vithas hospitals to perform many types of procedure with maximum precision and safety. Four new hybrid operating rooms will be installed across four of the group’s hospitals.

Next to this, Philips will replace the Vithas hospitals’ CT (Computed Tomography) equipment by high-end equipment, allowing them to perform more precise cardiac diagnoses thanks to the Philips equipment’s speed, coverage, and high image quality, while also minimizing radiation dose. The agreement also includes X-ray equipment, solutions for dose management, and a Corporate Network for Diagnostic Imaging.

Benefits of the Corporate Network for Diagnostic Imaging

Through this network, and thanks to a solution for reviewing, post-processing and sharing information from advanced medical imaging studies, more than 100 radiologists will be able to work in a unified way with access to tools that speed up and improve the quality of results. Likewise, more than 5,000 referring physicians will have higher quality radiological reports directly available to them via a clinical viewer. The solution will also improve the patient experience, because they will be able to view their reports and images from any PC or mobile device via a secure web portal.

Joint scientific research

The innovation and collaboration agreement between Philips and Vithas Group will make it possible for the two organizations to collaborate in technological innovation projects in Vithas Group reference centers. These projects will involve joint scientific research in key healthcare areas, as well as the training of Vithas Group professionals in new technologies and clinical procedures.
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Sachita Shah, Sr. Director, Global Health, Butterfly Network, "Butterfly is proud to continue improving maternal health equity through Phase Two of the largest-scale handheld ultrasound distribution and training ever conducted in Sub-Saharan Africa. South Africa is an emerging market that continues to have disproportionately high rates of maternal mortality and stillbirth. Patients need easier access to antenatal imaging, and clinicians need better capabilities for screening high-risk conditions that lead to disproportionately worse pregnancy outcomes in rural areas in the public sector. Together with CHAI and GUSI, we can tackle this by making ultrasound much more accessible, so high-risk conditions can be identified earlier in care, which is known to improve outcomes.”
The clinical Study will enroll up to 97 patients at up to 12 European investigational sites. Completion of the study is expected this year, and results will support CE mark and pre-market approval submissions reports Vivasure Medical.
Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.

By using this website you agree to accept Medical Device News Magazine Privacy Policy